Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice ...

Panelists discuss how bimekizumab demonstrated significant improvements in pain scores (from baseline levels around 60/100) and fatigue measures, with meaningful percentages of patients achieving ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical ...

Increasing the cholesterol-lowering protein ApoM in mice improved retinal health and may be the key to slowing age-related ...

Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance ...